NEW YORK, May 8, 2017 /PRNewswire/ -- The nationwide law firm of Bernstein Liebhard LLP is monitoring the growing litigation involving Onglyza and Kombiglyze XR, Type 2 diabetes medications allegedly associated with an increased risk of heart failure. According to recent report from The National Law Journal, between 150 and 200 product liability lawsuits have been filed against the manufacturers of these drugs nationwide, with more filings expected in the future.
Plaintiffs pursuing Onglyza and Kombiglyze XR lawsuits claim that AstraZeneca Pharmaceuticals and Bristol-Myers Squib knew that saxagliptin could raise an individual's risk of heart failure, but failed to provide doctors and patients with adequate warnings regarding this potential danger. They seek to recover compensation for medical bills, lost wages, pain and suffering, emotional distress and more.
"Our Firm has been contacted by many individuals who claim that their heart failure diagnosis was the result of treatment with Onglyza or Kombiglyze XR. We are not surprised that this litigation is growing at such a significant pace," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal reviews to individuals who were diagnosed with heart failure while being treated with Onglyza or Kombiglyze XR.
FDA Warnings for Onglyza and Kombiglyze XR
Onglyza (saxagliptin) was approved by the U.S. Food & Drug Administration (FDA) in July 2009 and is used in conjunction with diet and exercise to lower blood sugar in people with Type 2 diabetes. Kombiglyze XR (saxagliptin and metformin) was approved by the agency in November 2010.
The FDA began a safety review of saxagliptin in April 2014, after a clinical trial known as SAVOR suggested that the medication was associated with a 27% increase in hospitalizations for heart failure, as well as a higher risk of all-cause mortality. On April 14, 2015, the agency's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14-to-1 to recommend that new information regarding a potential association with heart failure be added to the labels of all saxagliptin-containing drugs.
A year later, the "Warnings and Precautions" sections of the Onglyza and Kombiglyze XR labels were modified to note their possible association with an increased risk of heart failure, particularly in patients with a history of heart and kidney disease. Individuals using these drugs should contact their doctor if they experience any signs or symptoms of heart failure, including:
- Unusual shortness of breath during daily activities
- Difficulty breathing when lying down
- Tiredness, weakness, or fatigue
- Weight gain with swelling in the ankles, feet, legs, or stomach
Type 2 diabetes patients who were diagnosed with heart failure while using Onglyza or Kombiglyze XR could be entitled to compensation from their manufacturers. To find out more about filing a Kombiglyze XR or Onglyza lawsuit, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/onglyza-lawsuit-attorneys-at-bernstein-liebhard-llp-comment-on-growing-heart-failure-litigation-involving-type-2-diabetes-medications-onglyza-and-kombiglyze-xr-300453268.html
SOURCE Bernstein Liebhard LLP